Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 11 (Table of Contents)
Published: 18 Nov-2013
DOI: 10.3833/pdr.v2013.i11.1990 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
After exiting antibiotics R&D in 2000 with the spin out of its anti-infectives discovery division into Basilea Pharmaceutica, Roche has highlighted its renewed commitment to the field by licensing global rights to develop and commercialise Polyphor’s macrocyclic antibiotic POL7080, which has potential in the treatment of multidrug-resistant Pseudomonas aeruginosa infections...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS